Head & Neck Cancers | Specialty

Dr. Randolph on Future Treatment Approaches in Thyroid Cancer

October 11th 2016

Gregory W. Randolph, MD, director, General and Thyroid Surgical Services, Massachusetts General Hospital, discusses the future methods of treating patients with thyroid cancer.

Dr. Jonas de Souza on the Impact of Pembrolizumab Approval in Head and Neck Cancer

October 5th 2016

​Jonas de Souza, MD, assistant professor of medicine, University of Chicago, discusses the approval of pembrolizumab for relapsed head and neck cancer patients who are platinum-refractory

KRAS-Variant HNSCC Outcomes May Improve With Cetuximab

October 4th 2016

Patients with head and neck cancer whose disease is associated with KRAS variant had significantly better progression-free survival and overall survival when treated with the monoclonal antibody cetuximab, according to findings of a retrospective analysis of a randomized trial.

New Classification System Reflects Improved Prognosis for HPV+ Oropharyngeal Cancer

September 22nd 2016

Researchers have created a new classification system for oropharyngeal cancer that is adjusted for the improved prognosis of patients with HPV-positive disease.

Published Results Affirm Efficacy of Fixed-Dose Pembrolizumab in HNSCC

September 22nd 2016

The FDA-approved fixed dose of 200 mg of pembrolizumab administered once every 3 weeks yielded durable responses in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Pembrolizumab Approval Is Tip of the Iceberg for Immunotherapy in HNSCC

September 21st 2016

Barbara A. Burtness, MD, discussed the potential role for immunotherapy in frontline head and neck cancer, as well as the possible benefit of using it in combination with standard treatments, including radiation and chemotherapy.

Dr. Burtness on Ongoing Trials of Immunotherapy in Head and Neck Cancer

September 21st 2016

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses some of the ongoing trials currently examining the use of immunotherapy to treat patients with head and neck cancer.

Dr. Frakes on Late Toxicities in HPV-Associated Oropharynx Squamous Cell Carcinoma

September 16th 2016

Jessica Frakes, MD, assistant member, Department of Radiation Oncology, Moffitt Cancer Center, discusses some of the late toxicities seen in patients with HPV-positive oropharynx squamous cell carcinoma.

Dr. Schoenfeld on Synergy Between Radiation and Immunotherapy in SCCHN

September 13th 2016

Dr. Anderson on Superoxide Dismutase Mimetic GC4419 in Treating Patients With Oropharyngeal Carcinoma

September 10th 2016

Carryn Anderson, MD, assistant professor of Radiation Oncology, University of Iowa, discusses a phase Ib/IIa study of superoxide dismutase mimetic GC4419 to reduce chemoradiotherapy-induced oral mucositis in patients with oral cavitiy or oropharyngeal carcinoma.

Dr. Randolph on Evolving Role of Surgery for Patients With Thyroid Cancer

September 6th 2016

Gregory W. Randolph, MD, director, General and Thyroid Surgical Services, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, discusses how the role of surgery has evolved for patients with thyroid cancer.

Dr. Joshua M. Bauml on the Impact of Pembrolizumab in Head and Neck Cancer

September 2nd 2016

Expert Says Nivolumab Poised to Change Standard of Care in SCCHN

August 23rd 2016

Robert L. Ferris, MD, PhD, discusses the findings of the CheckMate-141 study, potential biomarkers for nivolumab (Opdivo), and questions that remain regarding the use of the immunotherapy in squamous cell carcinoma of the head and neck.

Pembrolizumab to Have Critical Role in Head and Neck Cancer Treatment

August 21st 2016

Joshua M. Bauml, MD, discusses the impact of pembrolizumab's (Keytruda's) success in recurrent or metastatic head and neck squamous cell carcinoma, the results of the KEYNOTE-055 study, and what he sees on the horizon for the PD-1 inhibitor in this field.

Patient Resistance to Swallowing Exercises After Multimodality Therapy

August 17th 2016

Giselle Carnaby, PhD, professor, ASHA fellow, Communication Sciences and Disorders, University of Central Florida, discusses rehabilitation of swallowing after multimodality therapy in patients with head and neck cancer, and why they may be resistant to it.

Dr. Joshua M. Bauml on Pembrolizumab Versus Chemo in Head and Neck Cancers

August 16th 2016

Joshua M. Bauml, MD, assistant professor of Medicine, Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center, discusses the differences between pembrolizumab (Keytruda) and cytotoxic chemotherapies.

Dr. Nussenbaum on Organ Preservation for Patients With Larynx Cancer

August 10th 2016

Brian Nussenbaum, MD, Christy J. and Richard S. Hawes III Professor, Otolaryngology-Head and Neck Surgery, director, Head and Neck Surgical Oncology, vice chair of Clinical Affairs, patient safety officer, Washington University School of Medicine in St. Louis, discusses which patients with larynx cancer are eligible for organ preservation surgery.

FDA Approves Pembrolizumab for Head and Neck Cancer

August 6th 2016

The FDA has granted an accelerated approval to pembrolizumab as a treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma following progression on a platinum-based chemotherapy.

Dr. Ferris on FDA Approval of Pembrolizumab in Head and Neck Cancer

August 6th 2016

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and coleader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses the impact of the FDA approval of pembrolizumab (Keytruda) for the treatment of patients with head and neck cancer.

Dr. Ranee Mehra on the Importance of Symptom Management in Head and Neck Cancer

August 5th 2016